Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness

Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness

Triple ISO Certification Recognition Positions Company as a Standard-Bearer in Clinical Decision Support Quality Infrastructure

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Company"), a global leader in clinical decision support solutions applying patient-centric medication safety standards, today announced that Seegnal eHealth Ltd., its Israeli operating subsidiary, has been granted the prestigious Gold Mark by the Standards Institution of Israel, a high institutional quality distinction awarded to organizations that have embedded a culture of excellence across their management systems, processes, and product lifecycle. The Gold Mark certification further solidifies Seegnal's commercialization-readiness and its standing as an enterprise-grade platform trusted by leading healthcare systems.

A Landmark Recognition in Quality Leadership
The Gold Mark is conferred exclusively upon organizations that have adopted quality and excellence as a foundational organizational ethos, not merely as a compliance exercise, and that simultaneously hold three or more quality certification marks attesting to the alignment of their management systems, processes, and products with Israeli and international standards. It represents the intersection of institutional rigor, operational discipline, and an unwavering commitment to safety and performance.

Seegnal eHealth Ltd. received the Gold Mark in recognition of holding all three of the following certification marks, each issued by the Standards Institution of Israel:

  • ISO 13485:2016: Medical Devices Quality Management Systems, certifying that Seegnal's quality management processes meet the most demanding international standards applicable to medical device manufacturers and suppliers;
  • ISO 27799: Information Security Management in Health, confirming that Seegnal's data governance and information security architecture conform to sector-specific requirements for the handling of sensitive health data; and
  • ISO 27001:2022: Information Security Management Systems (ISMS), attesting to a certified and independently audited information security management framework across the organization.

The Gold Mark certificate for 2026 was signed by Dr. Gilad Golub, CEO of the Standards Institution of Israel, and Avital Weinberg, VP of the Quality & Certification Division.

About Seegnal Inc.
Seegnal Inc. (TSXV: SEGN) is a global leader in clinical decision support, applying patient-centric medication safety standards to improve outcomes across healthcare systems. Seegnal's proprietary platform is deployed at leading hospital networks and provides real-time, point-of-care medication safety intelligence. For more information, visit www.seegnal.com.

Contact Information
Elad Bibi-Aviv
Chief Executive Officer
+1 (929) 248 4652
Arx Investor Relations
North American Equities Desk
seegnal@arxhq.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Source

SEGN:CA
The Conversation (0)
Lexaria Updates Progress on Human Study #7

Lexaria Updates Progress on Human Study #7

KELOWNA, BC / ACCESS Newswire / May 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on Human Pilot Study #7 (GLP-1-H26-7) that will evaluate two oral DehydraTECH-semaglutide ("DHT-sema")... Keep Reading...
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

Inaugural Episode Features CEO Rich Christopher on DehydraTECH Platform, GLP-1 Market Opportunity and Commercial Strategy KELOWNA, BC / ACCESS Newswire / May 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, today... Keep Reading...
Lexaria Bioscience (NASDAQ:LEXX)

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on August 30, 2024 with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's... Keep Reading...
Hand places a blue block labeled "M&A" atop a pyramid of wooden blocks with business icons.

Fit to Work: GLP-1 and Metabolic Health in the M&A Sector

Biotechnology, pharmaceutical and medtech companies each contributed about 30 percent of deal volume to overall mergers and acquisitions (M&A) activity in 2025.The surge is attributed to rising obesity and diabetes cases, with the 2025 World Obesity Atlas projecting that the total number of... Keep Reading...
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Contracts signed for Animal Study #2: GLP-1-A26-2Amycretin and retatrutide to be tested for compatibility with DehydraTECH KELOWNA, BC / ACCESS Newswire / April 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is... Keep Reading...
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 3 Canadian Biotech Stocks in 2026

Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.Here the Investing News Network profiles the three best-performing Canadian biotech stocks... Keep Reading...

Interactive Chart

Latest Press Releases

Related News